Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. - Wikidata - awgldk - TriplyDB

Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

http://www.wikidata.org/entity/Q37287661

about

Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.

P2860

Q49446863-1C42C7E5-C167-43F6-849B-384B732F49B4

P2860

Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

http://www.wikidata.org/entity/Q37287661

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Fosfomycin Enhances the Activi ...... kinetic-Pharmacodynamic Model.

@en

Fosfomycin Enhances the Activi ...... kinetic-Pharmacodynamic Model.

@nl

type

label

Fosfomycin Enhances the Activi ...... kinetic-Pharmacodynamic Model.

@en

Fosfomycin Enhances the Activi ...... kinetic-Pharmacodynamic Model.

@nl

prefLabel

Fosfomycin Enhances the Activi ...... kinetic-Pharmacodynamic Model.

@en

Fosfomycin Enhances the Activi ...... kinetic-Pharmacodynamic Model.

@nl

P1433

Q37287661-E0527CC2-52D7-458A-A9AA-E2A7E237FF47

P1476

Q37287661-A22CB12D-DF5F-4D29-8D34-459FABDC321E

P2093

Q37287661-28099208-A573-401F-BD6F-981B26350CD2

Q37287661-2D680A45-844C-4E47-97EF-376E2CFA4889

Q37287661-335C18FC-0C1B-49A2-BDC3-4678BB5D65FA

Q37287661-98091229-8B4E-440D-B910-2DD37DF69F35

Q37287661-BA7FBFD2-5173-4DF2-8BF0-8449A22043AE

Q37287661-BEB51F2F-E624-4BEE-B7D1-E5D9309DB969

Q37287661-C1D06B0A-7BAA-41B1-A1B8-27F4212C4AC3

Q37287661-F53E54F4-0BC4-4813-995F-B9F74166BBD0

P2860

Q37287661-024B27D1-AE30-4239-9759-FCBADF7E6BBF

Q37287661-0B7AE203-4362-48D0-AADC-88DF1CA80D31

Q37287661-1B7DAA1A-282F-4259-8804-F6B1AF0C3E28

Q37287661-1D09DD9E-C65E-4FA5-961E-0F72493784DB

Q37287661-1F622647-F5CB-48C6-B784-22CE452D501B

Q37287661-20FD685D-C8E5-42F5-A2F3-4AEAE89237AF

Q37287661-2873D838-250F-4570-A641-01180A47EF80

Q37287661-28870B34-8C4C-4D7F-9568-B286E81A30BC

Q37287661-29A9AAB7-FE1E-46CC-AE9F-6520156571E5

Q37287661-2A982094-A6C8-423F-9D8F-B33E63EF2DDF

P304

Q37287661-E243CE7C-8420-4A84-A899-BA419E171074

P31

Q37287661-21D03D6C-D35E-479D-9293-FC0E22B92155

P356

Q37287661-8FA5F103-B8A5-48D5-B6A7-ED89AF312D02

P407

Q37287661-7267A82C-C006-40C1-9662-58A40BEE9004

P433

Q37287661-16A83AEE-B535-496B-AA01-EAADE0CBFB92

P478

Q37287661-640EBD28-0C9F-4365-BD1A-59A6B4E85A50

P50

Q37287661-E27EB0FE-3C57-4D9E-A864-24D64B20DB0B

P577

Q37287661-05849505-B1AE-44BA-8205-B6173D1C0FE7

P698

Q37287661-37712B02-B319-47B8-A1BB-C89279DB4749

P932

Q37287661-793684B4-D14A-4C8C-A494-4794A6571EDB

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Fosfomycin Enhances the Activi ...... okinetic-Pharmacodynamic Model

@en

P2093

Ashley D Hall Snyder

http://www.w3.org/2001/XMLSchema#string

George Sakoulas

http://www.w3.org/2001/XMLSchema#string

Joe Pogliano

http://www.w3.org/2001/XMLSchema#string

John P McRoberts

http://www.w3.org/2001/XMLSchema#string

Juwon Yim

http://www.w3.org/2001/XMLSchema#string

Michael J Rybak

http://www.w3.org/2001/XMLSchema#string

Nivedita Singh

http://www.w3.org/2001/XMLSchema#string

Poochit Nonejuie

http://www.w3.org/2001/XMLSchema#string

P2860

Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci

Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs.

Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content

Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions.

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

P304

5716-5723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00687-16

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27431211

http://www.w3.org/2001/XMLSchema#string

P932

5038233

http://www.w3.org/2001/XMLSchema#string